G-BA finds no additional benefit for Eylea, Aubagio

Germany's Federal Joint Committee (G-BA) issued final benefit assessments that found "no additional benefit" for Eylea aflibercept from Bayer AG (Xetra:BAYN) and Aubagio teriflunomide from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY). Both recommendations are in line with January preliminary assessments from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG).

G-BA said Bayer's Eylea has "no additional benefit" vs. Lucentis ranibizumab to treat visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). Bayer has ex-U.S. rights to Eylea from partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) (see BioCentury Extra, Jan. 2). ...